1st RRMS Patient Dosed in Phase 1/2 Trial of Immunotherapy IMCY-0141
Daniel Lorrain (@DSlorrain) / X
Discovery of remyelination therapeutics that overcome the effects of inflammatory macrophages on oligodendrocyte formation
Pipeline strikes $1B deal with Janssen for myelin restoration candidate in MS | BioWorld
Likelihood of Approval and Phase Transition Success Rate Model - PIPE-307 in Multiple Sclerosis - Market Research Reports & Consulting | GlobalData UK Ltd.
Likelihood of Approval and Phase Transition Success Rate Model - PIPE-307 in Multiple Sclerosis - Market Research Reports & Consulting | GlobalData UK Ltd.
Multiple Sclerosis Treatment Market Size, Share, Growth | forecast
J&J opens the valve on $50M MS partnership with Pipeline
Discovery of remyelination therapeutics that overcome the effects of inflammatory macrophages on oligodendrocyte formation
Likelihood of Approval and Phase Transition Success Rate Model - PIPE-307 in Multiple Sclerosis - Market Research Reports & Consulting | GlobalData UK Ltd.
Relapsing-Remitting Multiple Sclerosis Pipeline Drugs
Pipeline Therapeutics Receives IND Clearance from FDA to Initiate Phase 1b/2a Study of PIPE-307 in Patients with Relapsing-Remit
With MS & Fibrosis Trials Planned, J&J-Partnered Contineum Now Preps for IPO - MedCity News
Pipeline Testing MS Remyelinating Therapy PIPE-307 in Healthy People
PIPE-307 Shows Early Promise as a Neuroregenerative Treatment for MS
MS News That Caught My Eye: SPMS Transition, NVG-291, PIPE-307, Foralumab
Pipeline Therapeutics, Janssen partner for neuroscience therapy
PIPE-307, MS Therapy to Restore Myelin, Found Safe in Healthy Adults
RRMS Myelin-restoring Therapy PIPE-307 Cleared for Clinical Trial Testing
MS News That Caught My Eye: Cure Connections, PIPE-307, Temelimab, EHP-101
P130.02
